Free Trial

Immunovant (IMVT) Stock Forecast & Price Target

$28.00
+0.03 (+0.11%)
(As of 07/22/2024 ET)

Immunovant - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 15 Wall Street analysts who have issued ratings for Immunovant in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 15 have given a buy rating for IMVT.

Consensus Price Target

$49.73
77.62% Upside
High Forecast$57.00
Average Forecast$49.73
Low Forecast$40.00

According to the 15 analysts' twelve-month price targets for Immunovant, the average price target is $49.73. The highest price target for IMVT is $57.00, while the lowest price target for IMVT is $40.00. The average price target represents a forecasted upside of 77.62% from the current price of $28.00.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
17 Buy rating(s)
17 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$49.73$48.75$48.00$27.50
Forecasted Upside77.62% Upside40.53% Upside36.33% Upside50.77% Upside
Get Immunovant Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

IMVT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immunovant Stock vs. The Competition

TypeImmunovantMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside77.62% Upside3,004.08% Upside9.23% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Cantor Fitzgerald
3 of 5 stars
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
6/3/2024Oppenheimer
3 of 5 stars
 Lower TargetOutperform ➝ Outperform$50.00 ➝ $46.00+81.17%
5/30/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$51.00 ➝ $51.00+72.47%
3/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$48.00+47.69%
3/13/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+58.73%
2/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$51.00+37.36%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$55.00+45.50%
12/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$49.00 ➝ $51.00+31.61%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+25.69%
12/1/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$55.00 ➝ $56.00+39.83%
10/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$28.00 ➝ $57.00+64.74%
9/27/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$32.00 ➝ $48.00+14.75%
9/27/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$33.00 ➝ $50.00+25.13%
9/27/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$33.00 ➝ $48.00+20.12%
9/26/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$40.00+7.79%
7/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$28.00 ➝ $34.00+47.00%
7/10/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$14.00 ➝ $21.00+18.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:38 AM ET.

IMVT Forecast - Frequently Asked Questions

What is Immunovant's forecast for 2024?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunovant is $49.73, with a high forecast of $57.00 and a low forecast of $40.00.

Should I buy or sell Immunovant stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMVT shares.

Does Immunovant's stock price have much upside?

According to analysts, Immunovant's stock has a predicted upside of 40.14% based on their 12-month stock forecasts.

What analysts cover Immunovant?

Immunovant has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, and Oppenheimer in the past 90 days.

Do Wall Street analysts like Immunovant more than its competitors?

Analysts like Immunovant more than other "medical" companies. The consensus rating for Immunovant is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMVT compares to other companies.


This page (NASDAQ:IMVT) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners